Haisco Pharmaceutical Group Co., Ltd.

This study tests a new dry powder inhaler called HSK39004 in 180 adults aged 40 to 80 with COPD. The goal is to see if it improves lung function over 4 weeks compared to a placebo. Participants are randomly assigned to receive either the drug or an inactive inhaler, and neither t…

This study tests a new medicine called HSK39004, given as an inhaler, to see if it helps people with chronic obstructive pulmonary disease (COPD) breathe better. About 50 adults aged 40 to 80 with COPD will take either the study drug or a placebo for 4 weeks. The main goal is to …

This study is testing a new inhaled medication called HSK39004 for people with COPD. Researchers want to see how the drug moves through the body and if it improves lung function. A small group of 12 patients will try the new drug and a standard treatment to compare them.

This study looks at how the antifungal drug itraconazole changes the way the body processes HSK31858. It involves 24 healthy adults aged 18-45. Participants take HSK31858 with and without itraconazole to measure drug levels in the blood. This is a drug interaction study, not a tr…

This study looks at how the drug rifampicin changes the way another drug, HSK31858, is processed in the body. It involves 24 healthy adults aged 18 to 45. The goal is to measure drug levels in the blood, not to treat any disease.